Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06813365 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Dec 30, 2026 → Oct 30, 2027
See other at-risk trials from Dizal Pharmaceuticals

Record History

  1. Primary completion pushed from Dec 30, 2026 to Oct 30, 2027 Enrollment increased: 190 → 300 participants · Completion pushed from Jul 30, 2028 to Dec 30, 2028 · Eligibility criteria expanded, about 10 wordsv4 Show 3 more changesShow less
    • Enrollment increased: 190 → 300 participants
    • Completion pushed from Jul 30, 2028 to Dec 30, 2028
    • Eligibility criteria expanded, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 76 to 190 Primary completion date: Apr 30, 2026 to Dec 30, 2026 · Completion date: Jun 30, 2027 to Jul 30, 2028 · Eligibility criteria expanded, about 10 words · 1 morev3 Show 4 more changesShow less
    • Primary completion date: Apr 30, 2026 to Dec 30, 2026
    • Completion date: Jun 30, 2027 to Jul 30, 2028
    • Eligibility criteria expanded, about 10 words
    • Study description shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Secondary endpoints: details revised at 1 of 12 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.
Trial Details
NCT Number NCT06813365
Lead Sponsor Dizal Pharmaceuticals
Conditions Nonsmall-cell Lung Cancer
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov